We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-9.36%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$214M
AUM Growth
-$23.9M
Cap. Flow
+$5.9M
Cap. Flow %
2.76%
Top 10 Hldgs %
60.02%
Holding
48
New
12
Increased
9
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$4.89M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$3.99M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.32M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
5
KURA icon
Kura Oncology
KURA
+$2.63M

Top Sells

Rank Stock Value
1
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$4.46M
2
PYXS icon
Pyxis Oncology
PYXS
+$3.49M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$3.19M
4
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$2.47M
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.74%
2 Financials 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$28.1M 13.15%
554,000
+19,000
+4% +$839K
WHWK
2
Whitehawk Therapeutics
WHWK
$196M
$26M 12.13%
1,529,402
– –
VTGN icon
3
VistaGen Therapeutics
VTGN
$10.1M
$14.6M 6.8%
391,209
– –
CLDX icon
4
Celldex Therapeutics
CLDX
$2.96B
$11M 5.14%
322,898
-17,200
-5% -$550K
RLMD icon
5
Relmada Therapeutics
RLMD
$556M
$9.23M 4.31%
342,000
-62,000
-15% -$1.28M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.08M 4.24%
539,500
+69,500
+15% +$1.03M
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$8.32M 3.89%
843,122
– –
GHRS icon
8
GH Research
GHRS
$1.93B
$7.67M 3.59%
419,632
– –
KURA icon
9
Kura Oncology
KURA
$816M
$7.62M 3.56%
473,969
+182,085
+62% +$2.63M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.02B
$6.88M 3.21%
225,000
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$6.29M 2.94%
340,000
+22,000
+7% +$423K
MRUS
12
DELISTED
Merus
MRUS
$6.23M 2.91%
235,500
– –
BLU
13
DELISTED
BELLUS Health Inc.
BLU
$5.61M 2.62%
816,000
+291,000
+55% +$1.87M
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.52M 2.58%
813,500
+686,000
+538% +$4.89M
JYAC
15
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.52M 2.58%
562,500
– –
FULC icon
16
Fulcrum Therapeutics
FULC
$283M
$4.73M 2.21%
200,000
– –
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.32M 2.02%
52,500
+32,500
+163% +$3.32M
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$3.96M 1.85%
+580,000
New +$3.99M
OBIO icon
19
Orchestra BioMed
OBIO
$247M
$3.89M 1.82%
392,500
– –
ARWR icon
20
Arrowhead Research
ARWR
$12.1B
$3.79M 1.77%
82,500
-23,000
-22% -$1.14M
ACRS icon
21
Aclaris Therapeutics
ACRS
$772M
$3.75M 1.75%
217,600
+119,600
+122% +$1.63M
EYPT icon
22
EyePoint Inc
EYPT
$1.04B
$3.74M 1.75%
307,944
+64,872
+27% +$711K
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.7B
$3.58M 1.67%
206,126
– –
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.49M 1.63%
+33,200
New +$3.24M
PMVP icon
25
PMV Pharmaceuticals
PMVP
$59.7M
$2.82M 1.32%
+135,500
New +$2.39M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Acuta Capital Partners held 48 positions worth $214M, down 10% from $238M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q1 2022 filing shows 12 new, 9 increased, 9 reduced and 7 closed positions. Its largest new stake was Avadel Pharmaceuticals: 580,000 shares worth $3.96M. The largest sale was Cyteir Therapeutics, Inc. Common Stock, an estimated $4.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q1 2022 buy was Avadel Pharmaceuticals: 580,000 shares worth $3.96M.
  • Acuta Capital Partners added most to Jounce Therapeutics, Inc. Common Stock in Q1 2022, an estimated $4.89M increase.
  • Acuta Capital Partners's biggest Q1 2022 reduction was Pyxis Oncology, cutting an estimated $3.49M.
  • Acuta Capital Partners fully exited Cyteir Therapeutics, Inc. Common Stock in Q1 2022, selling an estimated $4.46M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $214M portfolio in Q1 2022.
  • Acuta Capital Partners opened 12 new positions and closed 7 in Q1 2022.
  • Acuta Capital Partners's portfolio value fell 10% quarter-over-quarter to $214M.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.